Email this article Low dose donor memory T-cell infusion after TCR alpha/beta depleted stem cell transplantation for patients with malignant disorders
- Authors: Blagov S.L.1, Shelikhova L.N.1, Osipova E.Y.1, Kiseleva V.V.1, Kazachenok A.S.1, Shekhovtsova Z.B.1, Bogoyavlenskaya A.A.1, Novichkova G.A.1, Maschan A.A.1, Maschan M.A.1
-
Affiliations:
- Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
- Issue: Vol 17, No 2 (2018)
- Pages: 9-20
- Section: PROMISING STUDIES
- Submitted: 20.09.2018
- Published:
- URL: https://hemoncim.com/jour/article/view/171
- DOI: https://doi.org/10.24287/1726-1708-2018-17-2-9-20
- ID: 171
Cite item
Full Text
Abstract
Viral infections are frequent complications in the recipients of the HSCT with TCRαβ and CD19-graft depletion. Adoptive transfer of memory T cells may improve immune response to common pathogens. The work reflects the retrospective safety analysis of using the infusions of CD45RA-depleted donor lymphocytes. Data from 80 patients were analyzed. Up to 3 doses of donor lymphocytes were administered at monthly intervals, escalating to 100 × 103/kg in haploidentical transplants and 300 × 103/kg in MUD transplants. Median follow-up for alive patients was 18 (8–44) months. We did not observe any allergic reactions, septic complications after infusion of donor lymphocytes (DLI). The cumulative incidence of a de novo acute GVHD after DLI was 5% (95% CI: 2–13). In 64% patients (n = 51) was detected CMV in the blood. There were no cases of resistant CMV disease on the background of drug therapy. In patients who received DLI, 70% (n = 56) had documented appearance of virus-specific lymphocytes in peripheral blood (Elispot assay). Thus, the introduction of memory T cells at a dose of 25–100 × 103/kg body weight of the recipient for CD3+ in the case of HSCT from a haploidentical donor and 100–300 × 103/kg for an unrelated HSCT. Infusions of low dose memory T-lymphocytes after transplant engraftment are safe, potentially effective and constitute a simple measure to prevent infections in the setting of alpha/beta T-cell-depleted transplantation.
Keywords
About the authors
S. L. Blagov
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
Author for correspondence.
Email: sblagov89@gmail.com
ORCID iD: 0000-0001-8754-1376
MD, Department of optimization treatment and prevention of complications of hematopoietic stem cell transplantation
Russia 117997, Moscow, Samory Mashela st., 1
Russian FederationL. N. Shelikhova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-0520-5630
E. Y. Osipova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-1873-3486
V. V. Kiseleva
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-3001-4820
A. S. Kazachenok
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-0497-9175
Z. B. Shekhovtsova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-9912-6572
A. A. Bogoyavlenskaya
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-9282-6883
G. A. Novichkova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-4911-0553
A. A. Maschan
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-0016-6698
M. A. Maschan
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-1735-0093
References
Supplementary files
